计算溶液所需的质量、体积或浓度。
提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存,干燥。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
INY-03-041 is a potent, highly selective and PROTAC-based pan- AKT degrader consisting of the ATP-competitive AKT inhibitor Ipatasertib conjugated to Lenalidomide . INY-03-041 inhibits AKT1 , AKT2 and AKT3 with IC 50 s of 2.0, 6.8 and 3.5 nM, respectively
In Vitro
INY-03-041 (10-1000 nM; 0-24 hours) induces potent degradation of all three AKT isoforms in MDA-MB-468 cells. INY-03-041 exhibits potent in vitro inhibition of S6K1 (IC 50 =37.3 nM) and PKG1 (IC 50 = 33.2 nM). INY-03-041 displays enhanced anti-proliferative effects compared with Ipatasertib in MDA-MB-468 and HCC1937 cells. INY-03-041 (250 nM, 12 h) promotes sustained AKT degradation and inhibition of downstream signaling effects for up to 96 h, even after compound washout. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: MDA-MB-468 cells Concentration: 10 nM, 50 nM, 100 nM, 250 nM, 500 nM, 1000 nM Incubation Time: 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours Result: Induced potent degradation of all three AKT isoforms in a dose-dependent manner after a 12-h treatment, with maximal degradation observed between 100 and 250 nM. At concentrations of 500 nM and greater, AKT degradation is diminished. Treatment with 250 nM of INY-03-041 over time reveals partial degradation of all AKT isoforms within 4 h and progressive loss of AKT abundance out to 24 h.
Form:Solid
IC50& Target:Akt1 2.0 nM (IC 50 ) Akt3 3.5 nM (IC 50 ) Akt2 6.8 nM (IC 50 ) Cereblon